Adcock Unhappy With Single Exit Price But Scoops ZAR1.8bn From ARV Tender
Executive Summary
Growing its portfolio of established brands and expanding its product range through the acquisition of non-regulated brands are at the top of Adcock Ingram’s wish-list in 2019, as the company grapples with what it feels is a “low” increase in South Africa’s single exit price and tough trading conditions in certain channels. Nevertheless, it saw a “sound” financial performance in the six months to 31 December 2018.
You may also be interested in...
Blitzima A Boost For Adcock As It Scoops Up New Rituximab Patients
South Africa’s Adcock Ingram gave a sprawling update of its operations for the first half of its financial year ending in June 2022, which saw a rise in sales but a decline in profit for its Prescription business.
Adcock Ingram Breaks Into Biosimilars With Infliximab
South African firm Adcock Ingram has described the launch of Celltrion’s Remsima (infliximab) biosimilar as “a really good step for us,” as it saw volumes plunge for its Prescription business during its financial year ended 30 June.
SA scheme opposes a rise in country’s SEP
South African body the Health Funders Association (HFA), which represents local stakeholders involved in funding private healthcare, has announced strong opposition to “any interim increase in medicine costs this year”. This comes in the wake of lobbying of government by industry for a further increase in the 2018 single exit price (SEP).